%D8%AF%D8%A7%D8%A8%D8%A7%D8%BA%D9%84%D9%8A%D9%81%D9%84%D9%88%D8%B2%D9%8A%D9%86Category:DapagliflozinDapagliflozinDapagliflozinDapagliflozinaDapaglifozine%D7%93%D7%90%D7%A4%D7%90%D7%92%D7%9C%D7%99%D7%A4%D7%9C%D7%95%D7%96%D7%99%D7%9FDapagliflozin%E3%83%80%E3%83%91%E3%82%B0%E3%83%AA%E3%83%95%E3%83%AD%E3%82%B8%E3%83%B3DapagliflozineDapagliflozinaDapagliflozinDapagliflozinQ409898%E8%BE%BE%E6%A0%BC%E5%88%97%E5%87%80
about
P2176
P3781
Dapagliflozin in patients with type 2 diabetes mellitus.Dapagliflozin lowers plasma glucose concentration and improves β-cell functionPharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.Dapagliflozin: drug profile and its role in individualized treatment.Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.Selective reaction monitoring of negative electrospray ionization acetate adduct ions for the bioanalysis of dapagliflozin in clinical studies.Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.[Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic ratsPharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover studyCost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Dapagliflozin
@de
Dapagliflozin
@it
Dapagliflozin
@nl
Dapagliflozin
@sh
Dapagliflozin
@sr
Dapagliflozina
@es
dapagliflozin
@en
dapagliflozin
@fr
dapagliflozina
@pt
דאפאגליפלוזין
@he
type
label
Dapagliflozin
@de
Dapagliflozin
@it
Dapagliflozin
@nl
Dapagliflozin
@sh
Dapagliflozin
@sr
Dapagliflozina
@es
dapagliflozin
@en
dapagliflozin
@fr
dapagliflozina
@pt
דאפאגליפלוזין
@he
altLabel
(2S,3R,4R,5S,6R)-2-(4-Chloro-3 ...... etrahydro-2H-pyran-3,4,5-triol
@en
BMS-512148
@en
Dapagliflozin
@en
Farxiga®
@en
Forxiga®
@en
prefLabel
Dapagliflozin
@de
Dapagliflozin
@it
Dapagliflozin
@nl
Dapagliflozin
@sh
Dapagliflozin
@sr
Dapagliflozina
@es
dapagliflozin
@en
dapagliflozin
@fr
dapagliflozina
@pt
דאפאגליפלוזין
@he